2026-06-14T05:08:20Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/167912025-05-09T08:57:36Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968

00925njm 22002777a 4500 dc Rose, Angela Mc author Nicolay, Nathalie author Sandonis-Martin, Virginia author Mazagatos, Clara author Petrović, Goranka author Baruch, Joaquin author Denayer, Sarah author Seyler, Lucie author Domegan, Lisa author Launay, Odile author Machado, Ausenda author Burgui, Cristina author Vaikutytė, Roberta author Niessen, F Annabel author Loghin, Isabela I author Husa, Petr author Aouali, Nassera author Panagiotakopoulos, George author Tolksdorf, Kristin author Horváth, Judit Krisztina author Howard, Jennifer author Pozo Sanchez, Francisco author Gallardo, Virtudes author Nonković, Diana author Džiugytė, Aušra author Bossuyt, Nathalie author Demuyser, Thomas author Duffy, Róisín author Luong Nguyen, Liem Binh author Kislaya, Irina author Martínez-Baz, Iván author Gefenaite, Giedre author Knol, Mirjam J author Popescu, Corneliu author Součková, Lenka author Simon, Marc author Michelaki, Stella author Reiche, Janine author Ferenczi, Annamária author Delgado-Sanz, Concepcion author Lovrić Makarić, Zvjezdana author Cauchi, John Paul author Barbezange, Cyril author Van Nedervelde, Els author O'Donnell, Joan author Durier, Christine author Guiomar, Raquel author Castilla, Jesús author Jonikaite, Indrė author Bruijning-Verhagen, Patricia Cjl author Lazar, Mihaela author Demlová, Regina author Wirtz, Gil author Amerali, Marina author Dürrwald, Ralf author Kunstár, Mihály Pál author Kissling, Esther author Bacci, Sabrina author Valenciano, Marta author I-MOVE-COVID-19 hospital study team author VEBIS hospital study team author 2023-11 Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose. Euro Surveill. 2023 Nov;28(47):2300187. 10.2807/1560-7917.ES.2023.28.47.2300187 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 37997665 http://hdl.handle.net/20.500.12105/16791 COVID-19 Europe SARS-CoV-2 Hospital Omicron Vaccine effectiveness Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022